--:--:--
Stockwatch Reports
…

Coverage / Healthcare / ADRX

Next Report: BPYPP
ADRXADARx Pharmaceuticals, Inc.

NasdaqGS · Healthcare · Mkt cap $2.1B · Avg vol 2.24M

$14.20

-0.71 (-4.76%)

Quote as of November 13, 2026, 4:47 PM ET

Initiating coverage · Published September 30, 2026, 4:02 PM ET

RNA-Targeting Biotech With a Late-Stage Cardiometabolic Pipeline

Share
$19.35$17.31$15.27$13.23Initiated · $20.20Sep 21Oct 12Nov 2Nov 13

Quote as of November 13, 2026, 4:47 PM ET

Company overview

ADARx Pharmaceuticals, Inc. (ADRX) is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics, with a primary focus on cardiometabolic and related diseases. The company's approach centers on designing RNA-based medicines intended to modulate disease-causing protein production at the source rather than managing symptoms downstream.

How it makes money: As a pre-revenue issuer — reflected in the N/A EPS figure — ADARx does not currently generate product revenue. Funding comes from equity capital raised in public markets (106.80M shares outstanding, 92.34M public float) and potentially from collaboration or licensing arrangements with larger pharmaceutical partners. Future revenue would derive from product sales upon approval, milestone payments, and royalties from partnered programs.

Customers: The end customers are patients and, indirectly, the payers and health systems that reimburse prescription therapies. In the near term, the relevant "customer" is the clinical trial site network and, for any partnership revenue, large-cap biopharma counterparties.

Scale: With a market capitalization of $2.1B and a public float of 92.34M shares, ADARx is a mid-cap clinical-stage biotech. Average daily volume of 2.24M shares provides adequate but not deep liquidity for institutional positioning.

Growth outlook

Near-term (0–18 months):

  • Clinical readouts from lead programs are the dominant near-term driver; timing and quality of data will determine whether the equity re-rates.
  • Cash management and any partnership announcements that extend runway without equity dilution.
  • Continued build-out of the pipeline beyond the lead asset, which would diversify the value proposition.

Medium-term (18–48 months):

  • Advancement into later-stage trials, which typically unlocks a broader institutional investor base and improves liquidity beyond the current 2.24M average volume.
  • Potential regulatory designations or accelerated pathways that shorten time-to-market for lead candidates.
  • Partnership or licensing economics that validate the platform externally and provide non-dilutive capital.

Growth in this model is not linear — it is step-function, driven by discrete clinical and regulatory events rather than quarterly compounding.

Financial analysis

Metric Historical (Est.) Near-Term (Est.) Medium-Term (Est.)
Revenue $0 (pre-revenue) $0–minimal Milestone/partnership dependent
R&D Expense Rising with trial activity Rising Rising, then plateauing
G&A Expense Moderate Moderate growth Scaling with organization
Operating Margin Negative Negative Negative until approval
EPS N/A N/A N/A
Shares Outstanding 106.80M Potential increase Potential increase
Market Cap $2.1B — —

The financial profile is that of a pre-commercial biotech: no revenue, negative operating margin, and an EPS figure that is not meaningful (reported as N/A). The critical financial variables are cash balance, burn rate, and share count. With 106.80M shares outstanding and a 92.34M public float, any future equity raise would be dilutive at meaningful scale, making non-dilutive funding sources — partnerships, grants, milestone payments — disproportionately valuable to per-share economics.

Industry & competitive landscape

Market size / TAM: The cardiometabolic therapeutic market is one of the largest in pharmaceuticals, spanning lipid disorders, metabolic disease, and related cardiovascular indications. RNA-targeting approaches address a subset of this market but target patient populations measured in the tens of millions globally. Even a modest captured share supports a multi-billion-dollar revenue opportunity.

Competitive positioning: ADARx competes on delivery technology, dosing convenience, and target selection. The RNA therapeutics field has become crowded, with several well-capitalized players. ADRX's differentiation must come from clinical data demonstrating superior durability or tolerability rather than from platform claims alone.

Named comparables:

  • Alnylam Pharmaceuticals (ALNY) — the established leader in RNA interference therapeutics, with approved products and a broad pipeline.
  • Ionis Pharmaceuticals (IONS) — a pioneer in antisense oligonucleotide therapeutics with multiple marketed products.
  • Arrowhead Pharmaceuticals (ARWR) — a clinical-stage RNAi company with a cardiometabolic and liver-focused pipeline, closely comparable in stage and strategy.
  • Amgen (AMGN) — a large-cap incumbent in cardiometabolic disease, relevant as both a potential partner and a competitive threat via marketed therapies.

Valuation

DCF discussion: A discounted cash flow analysis for a pre-revenue biotech is inherently probability-weighted. The appropriate framework is a risk-adjusted NPV: estimate peak sales for each pipeline asset, apply a probability of technical and regulatory success (typically 10–30% for early-stage programs, rising with phase), discount at a biotech-appropriate cost of equity (12–18%), and sum the contributions. Given no revenue base and an N/A EPS, the DCF output is highly sensitive to assumptions about peak penetration and launch timing — small changes in probability of success move fair value by hundreds of millions.

Comparable-company multiples:

Company Ticker Market Cap Revenue Multiple Stage
Alnylam Pharmaceuticals ALNY Large Cap Commercial-stage multiple Approved products
Ionis Pharmaceuticals IONS Large Cap Commercial-stage multiple Approved products
Arrowhead Pharmaceuticals ARWR Mid Cap Pre-revenue / pipeline Clinical-stage
Amgen AMGN Mega Cap Diversified multiple Commercial-stage
ADARx Pharmaceuticals ADRX $2.1B N/A (pre-revenue) Clinical-stage

Because ADRX has no revenue, standard multiples are not applicable (N/A). The most relevant comparison is to other clinical-stage RNA companies such as ARWR, where valuation is driven by pipeline NPV and cash position rather than earnings. At $2.1B, ADRX is priced in line with a mid-cap clinical-stage peer group — reasonable if the lead program is genuinely differentiated, rich if it is not.

Investment thesis

Pillar 1: RNA Interference as a Validated Modality

ADARx is developing RNA-targeting therapeutics, a modality with established clinical and commercial proof points in cardiometabolic and rare disease. The scientific foundation is no longer speculative — the question for ADRX is execution and differentiation. If the company's delivery chemistry and target selection translate into durable, infrequent dosing, the platform could support multiple independent value drivers rather than a single asset.

Pillar 2: Cardiometabolic Is a Large, Underpenetrated TAM

Cardiometabolic disease represents one of the largest pharmaceutical markets globally, with addressable populations in the hundreds of millions across dyslipidemia, hypertension-adjacent indications, and metabolic disorders. RNA therapeutics offer the potential for dosing intervals measured in months rather than days, a meaningful adherence advantage. Capturing even a low-single-digit share of a validated target class would support a revenue base well in excess of the current $2.1B market cap.

Pillar 3: Cash Runway Determines Optionality

As a pre-revenue issuer with EPS of N/A, ADARx's equity value is a function of pipeline NPV minus the probability of dilutive financing. The company's ability to reach its next clinical inflection point without materially impairing the 92.34M public float is the single most important determinant of per-share value. Investors should monitor cash disclosures at each reporting period as closely as trial data.

Pillar 4: Valuation Leaves Room for Positive Surprise

At $20.20, ADRX sits roughly 13% below its 52-week high of $23.21 and 9% above its 52-week low of $18.50. That compressed range, combined with a $2.1B market cap, implies the market is pricing a wide distribution of outcomes with a modest probability of success. A favorable readout would likely re-rate the equity toward or beyond the upper end of the range; a disappointing one would test the lower bound.

Risks

  • Clinical Trial Failure: The single largest risk. A negative readout in a lead program would likely remove a substantial portion of the $2.1B market cap, given the concentration of value in a small number of assets.
  • Dilutive Financing: With no revenue and N/A EPS, ADARx depends on external capital. A large equity raise would increase share count above 106.80M and pressure per-share value.
  • Competitive Intensity: Well-capitalized competitors including ALNY, IONS, ARWR, and AMGN are pursuing overlapping indications and could reach the market first with superior data.
  • Liquidity and Volatility: Average volume of 2.24M shares against a 92.34M float means institutional position-building and exit are both slow. Today's 667,863-share session and -2.09% move illustrate how thin trading can amplify price swings.
  • Regulatory and Reimbursement Uncertainty: Even successful trials face FDA review risk and, post-approval, payer pressure on pricing for high-cost biologics and RNA therapeutics.

Build your Watchlist & Portfolio

Last price

$14.20

Log in to add ADRX to your watchlist or simulate a trade.

Log in
Low$13.23High$20.20Initiate Price$20.20

Current $14.20

Coverage Metrics

Trend Direction

Down

Coverage High

$20.20

Coverage Low

$13.23

Initiate Price

$20.20

Current Price

$14.20

P&L

-29.70%

Quote as of November 13, 2026, 4:47 PM ET

Disclosure

This report was generated automatically by an AI-based research process, for educational and informational purposes only. It may not have been reviewed by a human for accuracy, completeness, or appropriateness prior to publication.

This report was not written or reviewed by a licensed securities analyst, investment adviser, or broker-dealer, and it does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security.

The rating, price target, and all financial estimates, projections, and comparisons in this report are model outputs generated from publicly available information, including market data, company filings, and news sources. They reflect known and unknown risks, uncertainties, and assumptions, and actual results may differ materially. Past performance is not indicative of future results.

Market and company data referenced in this report reflect the date the report was generated (or, for the "Current Price" figure shown separately from the report body, the most recent quote available when viewed) and may not reflect subsequent developments. StockWatch.report and its owners, employees, and contributors may hold long or short positions in any security discussed at any time.

Investing in securities involves risk, including the risk of loss of principal. You are solely responsible for your own investment decisions, and you should consult a licensed financial professional before making any investment decision based on this report. Use of this report and the Service is governed by, and subject to, our Terms and Conditions.

Key Data

Last

$20.20

Open

$20.65

Day Range

$19.42 - $21.61

P&L ($)

$-0.43

P&L (%)

-2.09%

Volume

667.86K

Previous Close

$20.63

Average Volume

2.24M

Rel. Volume

0.3×

Market Cap

$2.1B

Shares Outstanding

106.80M

Public Float

92.34M

As of September 30, 2026, 4:02 PM ET

Get the newsletter

Every trading day at 12:30 ET, free.

Advertise here
Stockwatch Reports

Free stock market updates, top gainers & losers, and AI-generated stock analyses — updated daily. Real-time price movements, quotes, and coverage for German & U.S. stoc